{"id":"https://openalex.org/W2188707596","doi":null,"title":"A Pharmacoeconomic Model for Making Value-Based Decisions About Serotonin Reuptake Inhibitors","display_name":"A Pharmacoeconomic Model for Making Value-Based Decisions About Serotonin Reuptake Inhibitors","publication_year":2005,"publication_date":"2005-02-01","ids":{"openalex":"https://openalex.org/W2188707596","mag":"2188707596"},"language":"en","primary_location":{"id":"mag:2188707596","doi":null,"is_oa":false,"landing_page_url":"https://arizona.pure.elsevier.com/en/publications/a-pharmacoeconomic-model-for-making-value-based-decisions-about-s","pdf_url":null,"source":{"id":"https://openalex.org/S4306521962","display_name":"P and T","issn_l":"1052-1372","issn":["1052-1372"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","poland-100"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"P and T","raw_type":null},"volume":null,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5018342431","display_name":"Patrick W. Sullivan","orcid":"https://orcid.org/0000-0002-3793-411X","observed_orcids":["https://orcid.org/0000-0002-3793-411X"]},"institutions":[{"id":"https://openalex.org/I51713134","display_name":"University of Colorado Anschutz","ror":"https://ror.org/03wmf1y16","country_code":"US","type":"education","lineage":["https://openalex.org/I51713134"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Patrick W. Sullivan","raw_affiliation_strings":["University of Colorado Anschutz Medical Campus"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Colorado Anschutz Medical Campus","institution_ids":["https://openalex.org/I51713134"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075196716","display_name":"Robert J. Valuck","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I921990950","display_name":"University of Colorado Denver","ror":"https://ror.org/02hh7en24","country_code":"US","type":"education","lineage":["https://openalex.org/I921990950"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert J. Valuck","raw_affiliation_strings":["University of Colorado Denver"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Colorado Denver","institution_ids":["https://openalex.org/I921990950"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040963321","display_name":"Diana I Brixner","orcid":"https://orcid.org/0000-0001-6637-6359","observed_orcids":["https://orcid.org/0000-0001-6637-6359"]},"institutions":[{"id":"https://openalex.org/I223532165","display_name":"University of Utah","ror":"https://ror.org/03r0ha626","country_code":"US","type":"education","lineage":["https://openalex.org/I223532165"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Diana Brixner","raw_affiliation_strings":["University of Utah"],"raw_orcid":"https://orcid.org/0000-0001-6637-6359","affiliations":[{"raw_affiliation_string":"University of Utah","institution_ids":["https://openalex.org/I223532165"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5015882459","display_name":"Edward P. Armstrong","orcid":"https://orcid.org/0000-0003-4147-3384","observed_orcids":["https://orcid.org/0000-0003-4147-3384"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Edward P. Armstrong","raw_affiliation_strings":["Pharmacy Practice and Science"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmacy Practice and Science","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"30","issue":"2","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.9467999935150146,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.9467999935150146,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.025299999862909317,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T11071","display_name":"Treatment of Major Depression","score":0.016699999570846558,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/serotonin-reuptake-inhibitors","display_name":"serotonin reuptake inhibitors","score":0.9909999966621399},{"id":"https://openalex.org/keywords/selective-serotonin-reuptake-inhibitors","display_name":"selective serotonin reuptake inhibitors","score":0.8640000224113464},{"id":"https://openalex.org/keywords/serotonin-norepinephrine-reuptake-inhibitors","display_name":"serotonin-norepinephrine reuptake inhibitors","score":0.9570000171661377},{"id":"https://openalex.org/keywords/antidepressants","display_name":"antidepressants","score":0.675000011920929},{"id":"https://openalex.org/keywords/managed-care","display_name":"managed care","score":0.5389999747276306},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.7850000262260437},{"id":"https://openalex.org/keywords/adverse-drug-reactions","display_name":"adverse drug reactions","score":0.9549999833106995},{"id":"https://openalex.org/keywords/treatment-discontinuation","display_name":"treatment discontinuation","score":0.6970000267028809},{"id":"https://openalex.org/keywords/pharmacy-and-therapeutics-committee","display_name":"pharmacy and therapeutics committees","score":0.7900000214576721},{"id":"https://openalex.org/keywords/drug-cost-containment","display_name":"drug cost containment","score":0.6100000143051147},{"id":"https://openalex.org/keywords/decision-analytic-model","display_name":"decision-analytic model","score":0.7900000214576721}],"concepts":[{"id":"https://openalex.org/C100406419","wikidata":"https://www.wikidata.org/wiki/Q3543802","display_name":"Formulary","level":2,"score":0.7605862021446228},{"id":"https://openalex.org/C104863432","wikidata":"https://www.wikidata.org/wiki/Q614304","display_name":"Pharmacy","level":2,"score":0.6225491762161255},{"id":"https://openalex.org/C2778176773","wikidata":"https://www.wikidata.org/wiki/Q2976049","display_name":"Drug class","level":3,"score":0.6112512350082397},{"id":"https://openalex.org/C2779343474","wikidata":"https://www.wikidata.org/wiki/Q3109175","display_name":"Context (archaeology)","level":2,"score":0.5603858828544617},{"id":"https://openalex.org/C31487548","wikidata":"https://www.wikidata.org/wiki/Q4859664","display_name":"Reuptake inhibitor","level":4,"score":0.553315281867981},{"id":"https://openalex.org/C2780265253","wikidata":"https://www.wikidata.org/wiki/Q1416012","display_name":"Managed care","level":3,"score":0.4860883057117462},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.47625207901000977},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.45433881878852844},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.4193047285079956},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.4050920009613037},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.34304529428482056},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.31625938415527344},{"id":"https://openalex.org/C160735492","wikidata":"https://www.wikidata.org/wiki/Q31207","display_name":"Health care","level":2,"score":0.22593840956687927},{"id":"https://openalex.org/C512399662","wikidata":"https://www.wikidata.org/wiki/Q3505712","display_name":"Family medicine","level":1,"score":0.13663703203201294},{"id":"https://openalex.org/C2779177272","wikidata":"https://www.wikidata.org/wiki/Q76560","display_name":"Antidepressant","level":3,"score":0.12312281131744385},{"id":"https://openalex.org/C162324750","wikidata":"https://www.wikidata.org/wiki/Q8134","display_name":"Economics","level":0,"score":0.10795828700065613},{"id":"https://openalex.org/C50522688","wikidata":"https://www.wikidata.org/wiki/Q189833","display_name":"Economic growth","level":1,"score":0.0},{"id":"https://openalex.org/C151730666","wikidata":"https://www.wikidata.org/wiki/Q7205","display_name":"Paleontology","level":1,"score":0.0},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0},{"id":"https://openalex.org/C558461103","wikidata":"https://www.wikidata.org/wiki/Q154430","display_name":"Anxiety","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:2188707596","doi":null,"is_oa":false,"landing_page_url":"https://arizona.pure.elsevier.com/en/publications/a-pharmacoeconomic-model-for-making-value-based-decisions-about-s","pdf_url":null,"source":{"id":"https://openalex.org/S4306521962","display_name":"P and T","issn_l":"1052-1372","issn":["1052-1372"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","poland-100"],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"P and T","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9391000270843506,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":19,"referenced_works":["https://openalex.org/W23710843","https://openalex.org/W1443187563","https://openalex.org/W1982499183","https://openalex.org/W2003363634","https://openalex.org/W2025976960","https://openalex.org/W2027923042","https://openalex.org/W2031602220","https://openalex.org/W2067157495","https://openalex.org/W2068083208","https://openalex.org/W2068434707","https://openalex.org/W2069090735","https://openalex.org/W2120455340","https://openalex.org/W2137296158","https://openalex.org/W2149841463","https://openalex.org/W2151845762","https://openalex.org/W2158910272","https://openalex.org/W2168715671","https://openalex.org/W2169496899","https://openalex.org/W2907257818"],"related_works":["https://openalex.org/W2067157495","https://openalex.org/W2915982999","https://openalex.org/W72641942","https://openalex.org/W1995125629","https://openalex.org/W7075602190","https://openalex.org/W1987719831","https://openalex.org/W2090525786","https://openalex.org/W2415684592","https://openalex.org/W7095452437","https://openalex.org/W2466748673"],"abstract_inverted_index":{"Managed":[0],"care":[1,109],"organizations":[2],"and":[3,61,63,77,102,131,134,141,154],"pharmacy":[4,140],"benefit":[5],"managers":[6],"often":[7],"use":[8],"tiered":[9],"formularies":[10],"to":[11,20],"contain":[12],"drug":[13,74],"costs.":[14],"Cost":[15],"is":[16],"one":[17],"factor":[18],"used":[19],"decide":[21],"tier":[22],"placement.":[23],"Drug":[24],"prices":[25],"alone":[26],"may":[27],"not":[28],"reflect":[29],"the":[30,44,82,92,97,114,123,127,149],"true":[31],"cost":[32],"of":[33,43,50,72,104,117,151],"using":[34],"particular":[35],"drugs":[36,156],"within":[37],"a":[38,107,137],"class.":[39,159],"A":[40],"decision-analytic":[41],"model":[42,69,95,128],"serotonin":[45,57,62],"reuptake":[46,58,65],"inhibitor":[47],"(SRI)":[48],"class":[49],"antidepressants":[51],"was":[52,129],"reviewed.":[53],"SRIs":[54,105],"include":[55],"selective":[56],"inhibitors":[59,66],"(SSRIs)":[60],"norepinephrine":[64],"(SNRIs).":[67],"The":[68,94],"uses":[70],"rates":[71,79],"adverse":[73],"reactions":[75],"(ADRs)":[76],"discontinuation":[78],"found":[80],"in":[81,106,125,157],"products\u2019":[83],"prescribing":[84],"information,":[85],"along":[86],"with":[87,148],"other":[88],"probabilities":[89],"derived":[90],"from":[91],"literature.":[93],"estimates":[96],"overall":[98],"direct":[99],"medical":[100,115],"costs":[101],"costeffectiveness":[103],"managed":[108],"setting,":[110],"taking":[111],"into":[112],"account":[113],"consequences":[116],"treatment-emergent":[118],"ADRs.":[119],"This":[120],"paper":[121],"discusses":[122],"context":[124],"which":[126],"constructed":[130],"its":[132],"strengths":[133],"weaknesses":[135],"as":[136],"tool":[138],"for":[139],"therapeutics":[142],"(P&T)":[143],"committees":[144],"that":[145],"are":[146],"faced":[147],"challenge":[150],"evaluating":[152],"new":[153],"current":[155],"this":[158]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}